{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:38:42Z","timestamp":1793932722483,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17483-3","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:03:48Z","timestamp":1756767828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beta blockers linked to reduced 1-Year mortality in critically ill congestive heart failure patients with differential benefits across subgroups"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-1691","authenticated-orcid":false,"given":"Kai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"17483_CR1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/circresaha.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger, V. L. Epidemiology of heart failure: A contemporary perspective. Circul. Res. 128, 1421\u20131434. https:\/\/doi.org\/10.1161\/circresaha.121.318172 (2021).","journal-title":"Circul. Res."},{"key":"17483_CR2","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1002\/ehf2.14915","volume":"11","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Global trends in heart failure from 1990 to 2019: an age-period-cohort analysis from the global burden of disease study. ESC Heart Fail. 11, 3264\u20133278. https:\/\/doi.org\/10.1002\/ehf2.14915 (2024).","journal-title":"ESC Heart Fail."},{"key":"17483_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cardfail.2022.02.015","volume":"28","author":"JC Jentzer","year":"2022","unstructured":"Jentzer, J. C. et al. Outcomes and predictors of mortality among cardiac intensive care unit patients with heart failure. J. Card. Fail. 28, 1088\u20131099. https:\/\/doi.org\/10.1016\/j.cardfail.2022.02.015 (2022).","journal-title":"J. Card. Fail."},{"key":"17483_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jacc.2018.11.054","volume":"73","author":"DA Pascual-Figal","year":"2019","unstructured":"Pascual-Figal, D. A. et al. The Interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. 73, 1016\u20131025. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.054 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"17483_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/circulationaha.122.060860","volume":"147","author":"Y Higashikuni","year":"2023","unstructured":"Higashikuni, Y. et al. NLRP3 inflammasome activation through Heart-Brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. Circulation 147, 338\u2013355. https:\/\/doi.org\/10.1161\/circulationaha.122.060860 (2023).","journal-title":"Circulation"},{"key":"17483_CR6","doi-asserted-by":"publisher","unstructured":"McDonagh, T. A. et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure 26, 5\u201317 (2024). (2023). https:\/\/doi.org\/10.1002\/ejhf.3024","DOI":"10.1002\/ejhf.3024"},{"key":"17483_CR7","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/ehf2.14284","volume":"10","author":"M Leite","year":"2023","unstructured":"Leite, M. et al. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. ESC Heart Fail. 10, 1822\u20131834. https:\/\/doi.org\/10.1002\/ehf2.14284 (2023).","journal-title":"ESC Heart Fail."},{"key":"17483_CR8","doi-asserted-by":"publisher","first-page":"e2231963","DOI":"10.1001\/jamanetworkopen.2022.31963","volume":"5","author":"B Xiang","year":"2022","unstructured":"Xiang, B., Zhang, R., Wu, X. & Zhou, X. Optimal Pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: A Meta-analysis. JAMA Netw. Open. 5, e2231963. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31963 (2022).","journal-title":"JAMA Netw. Open."},{"key":"17483_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","volume":"7","author":"AA Bhagat","year":"2019","unstructured":"Bhagat, A. A. et al. Continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail. 7, 1\u201312. https:\/\/doi.org\/10.1016\/j.jchf.2018.06.011 (2019).","journal-title":"JACC Heart Fail."},{"key":"17483_CR10","doi-asserted-by":"publisher","first-page":"e004675","DOI":"10.1161\/jaha.116.004675","volume":"6","author":"LG Gilstrap","year":"2017","unstructured":"Gilstrap, L. G. et al. Initiation, continuation, or withdrawal of Angiotensin-Converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J. Am. Heart Association. 6, e004675. https:\/\/doi.org\/10.1161\/jaha.116.004675 (2017).","journal-title":"J. Am. Heart Association"},{"key":"17483_CR11","doi-asserted-by":"publisher","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","volume":"2","author":"DN Silverman","year":"2019","unstructured":"Silverman, D. N. et al. Association of \u03b2-Blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: A secondary analysis of the TOPCAT trial. JAMA Netw. Open. 2, e1916598. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16598 (2019).","journal-title":"JAMA Netw. Open."},{"key":"17483_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","volume":"11","author":"SV Arnold","year":"2023","unstructured":"Arnold, S. V. et al. Beta-Blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. JACC Heart Fail. 11, 893\u2013900. https:\/\/doi.org\/10.1016\/j.jchf.2023.03.017 (2023).","journal-title":"JACC Heart Fail."},{"key":"17483_CR13","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","volume":"78","author":"P Palau","year":"2021","unstructured":"Palau, P. et al. Effect of \u03b2-Blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 78, 2042\u20132056. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.073 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"17483_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","volume":"12","author":"A Peikert","year":"2024","unstructured":"Peikert, A. et al. Contemporary use and implications of Beta-Blockers in patients with HFmrEF or hfpef: the DELIVER trial. JACC Heart Fail. 12, 631\u2013644. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.007 (2024).","journal-title":"JACC Heart Fail."},{"key":"17483_CR15","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.cpcardiol.2024.102376","volume":"49","author":"R Kaddoura","year":"2024","unstructured":"Kaddoura, R. et al. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis. Curr. Probl. Cardiol. 49, 102376. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102376 (2024).","journal-title":"Curr. Probl. Cardiol."},{"key":"17483_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejhf.3383","volume":"27","author":"S Matsumoto","year":"2025","unstructured":"Matsumoto, S. et al. Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. Eur. Heart J. 27, 124\u2013139. https:\/\/doi.org\/10.1002\/ejhf.3383 (2025).","journal-title":"Eur. Heart J."},{"key":"17483_CR17","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ van Veldhuisen","year":"2009","unstructured":"van Veldhuisen, D. J. et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart Failure). J. Am. Coll. Cardiol. 53, 2150\u20132158. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.046 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"17483_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3648","author":"A Abdin","year":"2025","unstructured":"Abdin, A. et al. Ivabradine improves win ratios of heart failure outcomes in patients with reduced ejection fraction - insights from the SHIFT trial. Eur. J. Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3648 (2025).","journal-title":"Eur. J. Heart Fail."},{"key":"17483_CR19","doi-asserted-by":"publisher","first-page":"105257","DOI":"10.1016\/j.ebiom.2024.105257","volume":"106","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Blood pressure response index and clinical outcomes in patients with septic shock: a multicenter cohort study. EBioMedicine 106, 105257. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105257 (2024).","journal-title":"EBioMedicine"},{"key":"17483_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama 315, 801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287 (2016).","journal-title":"Jama"},{"key":"17483_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s0140-6736(24)00139-9","volume":"403","author":"MA Mansournia","year":"2024","unstructured":"Mansournia, M. A. & Nazemipour, M. Recommendations for accurate reporting in medical research statistics. Lancet 403, 611\u2013612. https:\/\/doi.org\/10.1016\/s0140-6736(24)00139-9 (2024).","journal-title":"Lancet"},{"key":"17483_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/m16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-Value. Ann. Intern. Med. 167, 268\u2013274. https:\/\/doi.org\/10.7326\/m16-2607 (2017).","journal-title":"Ann. Intern. Med."},{"key":"17483_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy, S. P., Kakkar, R., McCarthy, C. P. & Januzzi, J. L. Jr. Inflammation in heart failure: JACC State-of-the-Art review. J. Am. Coll. Cardiol. 75, 1324\u20131340. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.014 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"17483_CR24","doi-asserted-by":"publisher","first-page":"21672","DOI":"10.1038\/s41598-024-72137-0","volume":"14","author":"E Santas","year":"2024","unstructured":"Santas, E. et al. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure. Sci. Rep. 14, 21672. https:\/\/doi.org\/10.1038\/s41598-024-72137-0 (2024).","journal-title":"Sci. Rep."},{"key":"17483_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2307\/2531492","volume":"45","author":"MS Pepe","year":"1989","unstructured":"Pepe, M. S. & Fleming, T. R. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics 45, 497\u2013507 (1989).","journal-title":"Biometrics"},{"key":"17483_CR26","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.3390\/ijms25158058","volume":"25","author":"AM Eraky","year":"2024","unstructured":"Eraky, A. M. et al. Beta-Blockers as an Immunologic and autonomic manipulator in critically ill patients: A review of the recent literature. Int. J. Mol. Sci. 25, 8058. https:\/\/doi.org\/10.3390\/ijms25158058 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"17483_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ejhf.1835","volume":"22","author":"J Cautela","year":"2020","unstructured":"Cautela, J. et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur. J. Heart Fail. 22, 1357\u20131365. https:\/\/doi.org\/10.1002\/ejhf.1835 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"17483_CR28","doi-asserted-by":"publisher","first-page":"1448015","DOI":"10.3389\/fphar.2024.1448015","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Impact of \u03b2-blockers on in-hospital mortality in patients with heart failure: a retrospective propensity-score matched analysis based on MIMIC-IV database. Front. Pharmacol. 15, 1448015. https:\/\/doi.org\/10.3389\/fphar.2024.1448015 (2024).","journal-title":"Front. Pharmacol."},{"key":"17483_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.11909\/j.issn.1671-5411.2021.01.005","volume":"18","author":"J Mart\u00ednez-Milla","year":"2021","unstructured":"Mart\u00ednez-Milla, J. et al. Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. J. Geriatric Cardiology: JGC. 18, 20\u201329. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2021.01.005 (2021).","journal-title":"J. Geriatric Cardiology: JGC"},{"key":"17483_CR30","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.jacc.2019.10.012","volume":"74","author":"A Deswal","year":"2019","unstructured":"Deswal, A. Heart failure with reduced ejection fraction and renal dysfunction: Beta-Blockers do not disappoint. J. Am. Coll. Cardiol. 74, 2905\u20132907. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.012 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"17483_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00392-018-1409-x","volume":"108","author":"IR Mordi","year":"2019","unstructured":"Mordi, I. R. et al. Prognostic significance of changes in heart rate following Uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clin. Res. Cardiol. 108, 797\u2013805. https:\/\/doi.org\/10.1007\/s00392-018-1409-x (2019).","journal-title":"Clin. Res. Cardiol."},{"key":"17483_CR32","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.echo.2019.06.017","volume":"32","author":"JJ Park","year":"2019","unstructured":"Park, J. J. et al. Myocardial strain for identification of \u03b2-Blocker responders in heart failure with preserved ejection fraction. J. Am. Soc. Echocardiography: Official Publication Am. Soc. Echocardiography. 32, 1462\u20131469e1468. https:\/\/doi.org\/10.1016\/j.echo.2019.06.017 (2019).","journal-title":"J. Am. Soc. Echocardiography: Official Publication Am. Soc. Echocardiography"},{"key":"17483_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/hjh.0000000000001856","volume":"37","author":"G Seravalle","year":"2019","unstructured":"Seravalle, G. et al. Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. J. Hypertens. 37, 443\u2013448. https:\/\/doi.org\/10.1097\/hjh.0000000000001856 (2019).","journal-title":"J. Hypertens."},{"key":"17483_CR34","doi-asserted-by":"publisher","unstructured":"Chung, C. M. et al. Cardioselective Versus Nonselective \u03b2-Blockers After Myocardial Infarction in Adults With Chronic Obstructive Pulmonary Disease. Mayo Clinic proceedings 97, 531\u2013546 (2022). https:\/\/doi.org\/10.1016\/j.mayocp.2021.07.020","DOI":"10.1016\/j.mayocp.2021.07.020"},{"key":"17483_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00392-024-02451-0","volume":"113","author":"J Ibrahim","year":"2024","unstructured":"Ibrahim, J. et al. Beta blockers are associated with lower all-cause mortality among HFpEF patients. Clin. Res. Cardiol. 113, 951\u2013958. https:\/\/doi.org\/10.1007\/s00392-024-02451-0 (2024).","journal-title":"Clin. Res. Cardiol."},{"key":"17483_CR36","doi-asserted-by":"publisher","unstructured":"Yang, Y. et al. Decreased mortality with Beta-Blocker therapy in HFpEF patients associated with atrial fibrillation. Cardiol. Res. Pract. 2020 (3059864). https:\/\/doi.org\/10.1155\/2020\/3059864 (2020).","DOI":"10.1155\/2020\/3059864"},{"key":"17483_CR37","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","volume":"27","author":"M Meyer","year":"2021","unstructured":"Meyer, M. et al. Association between \u03b2-Blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry. J. Card. Fail. 27, 1165\u20131174. https:\/\/doi.org\/10.1016\/j.cardfail.2021.04.015 (2021).","journal-title":"J. Card. Fail."},{"key":"17483_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-Neprilysin Inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655 (2019).","journal-title":"N. Engl. J. Med."},{"key":"17483_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jchf.2024.03.009","volume":"12","author":"N Reza","year":"2024","unstructured":"Reza, N. et al. Real-World experience and 36-Week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with Mavacamten. JACC Heart Fail. 12, 1123\u20131125. https:\/\/doi.org\/10.1016\/j.jchf.2024.03.009 (2024).","journal-title":"JACC Heart Fail."},{"key":"17483_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","volume":"10","author":"SJ Shah","year":"2025","unstructured":"Shah, S. J. et al. Cardiac myosin Inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 10, 170\u2013175. https:\/\/doi.org\/10.1001\/jamacardio.2024.3810 (2025).","journal-title":"JAMA Cardiol."},{"key":"17483_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cjca.2020.12.006","volume":"37","author":"MB Badrov","year":"2021","unstructured":"Badrov, M. B., Mak, S. & Floras, J. S. Cardiovascular autonomic disturbances in heart failure with preserved ejection fraction. Can. J. Cardiol. 37, 609\u2013620. https:\/\/doi.org\/10.1016\/j.cjca.2020.12.006 (2021).","journal-title":"Can. J. Cardiol."},{"key":"17483_CR42","doi-asserted-by":"publisher","unstructured":"Freire, B. M., de Melo, F. M. & Basso, A. S. Adrenergic signaling regulation of macrophage function: do we understand it yet? Immunotherapy advances 2, ltac010 (2022). https:\/\/doi.org\/10.1093\/immadv\/ltac010","DOI":"10.1093\/immadv\/ltac010"},{"key":"17483_CR43","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.1038\/s41598-022-12385-0","volume":"12","author":"N Girerd","year":"2022","unstructured":"Girerd, N. et al. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. Sci. Rep. 12, 8574. https:\/\/doi.org\/10.1038\/s41598-022-12385-0 (2022).","journal-title":"Sci. Rep."},{"key":"17483_CR44","doi-asserted-by":"publisher","first-page":"176858","DOI":"10.1016\/j.ejphar.2024.176858","volume":"980","author":"H Liu","year":"2024","unstructured":"Liu, H., Magaye, R., Kaye, D. M. & Wang, B. H. Heart failure with preserved ejection fraction: the role of inflammation. Eur. J. Pharmacol. 980, 176858. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176858 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"17483_CR45","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms25020794","volume":"25","author":"L Stoicescu","year":"2024","unstructured":"Stoicescu, L., Cri\u015fan, D., Morgovan, C., Avram, L. & Ghibu, S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int. J. Mol. Sci. 25, 794. https:\/\/doi.org\/10.3390\/ijms25020794 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"17483_CR46","doi-asserted-by":"publisher","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","volume":"111","author":"P Theofilis","year":"2022","unstructured":"Theofilis, P. et al. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. Int. Immunopharmacol. 111, 109080. https:\/\/doi.org\/10.1016\/j.intimp.2022.109080 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"17483_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963 (2023).","journal-title":"N. Engl. J. Med."},{"key":"17483_CR48","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with Obesity-Related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa2313917 (2024).","journal-title":"N. Engl. J. Med."},{"key":"17483_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug, B. A. et al. Effects of Tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat. Med. 31, 544\u2013551. https:\/\/doi.org\/10.1038\/s41591-024-03374-z (2025).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17483-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:35:57Z","timestamp":1757475357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17483-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32263"}}